ATE212026T1 - Halo-substituierte protein kinase c inhibitoren - Google Patents

Halo-substituierte protein kinase c inhibitoren

Info

Publication number
ATE212026T1
ATE212026T1 AT97302996T AT97302996T ATE212026T1 AT E212026 T1 ATE212026 T1 AT E212026T1 AT 97302996 T AT97302996 T AT 97302996T AT 97302996 T AT97302996 T AT 97302996T AT E212026 T1 ATE212026 T1 AT E212026T1
Authority
AT
Austria
Prior art keywords
protein kinase
halo
inhibitors
substituted protein
compounds
Prior art date
Application number
AT97302996T
Other languages
English (en)
Inventor
Peter G Goekjian
Michael R Jirousek
Guo-Zhang Wu
Original Assignee
Univ Mississippi
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mississippi, Lilly Co Eli filed Critical Univ Mississippi
Application granted granted Critical
Publication of ATE212026T1 publication Critical patent/ATE212026T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
AT97302996T 1996-05-01 1997-05-01 Halo-substituierte protein kinase c inhibitoren ATE212026T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1638296P 1996-05-01 1996-05-01

Publications (1)

Publication Number Publication Date
ATE212026T1 true ATE212026T1 (de) 2002-02-15

Family

ID=21776838

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97302996T ATE212026T1 (de) 1996-05-01 1997-05-01 Halo-substituierte protein kinase c inhibitoren

Country Status (21)

Country Link
US (1) US5936084A (de)
EP (1) EP0805158B1 (de)
JP (1) JP3235840B2 (de)
KR (1) KR20000065137A (de)
AT (1) ATE212026T1 (de)
AU (1) AU703395B2 (de)
BR (1) BR9709301A (de)
CA (1) CA2252701C (de)
CZ (1) CZ347098A3 (de)
DE (1) DE69709568T2 (de)
DK (1) DK0805158T3 (de)
EA (1) EA001450B1 (de)
ES (1) ES2170918T3 (de)
IL (1) IL126762A0 (de)
NO (1) NO310416B1 (de)
NZ (1) NZ332658A (de)
PL (1) PL329681A1 (de)
PT (1) PT805158E (de)
TR (1) TR199802193T2 (de)
WO (1) WO1997041127A1 (de)
YU (1) YU48398A (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US7425537B2 (en) * 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
ATE301661T1 (de) 2000-12-08 2005-08-15 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
MXPA04004026A (es) * 2001-10-29 2004-07-08 Nektar Therapeutics Al Corp Conjugados polimericos de inhibidores de la proteina quinasa c.
MXPA04011472A (es) 2002-05-22 2005-02-14 Amgen Inc Derivados de amino-piridina, piridina y piridazina para usarse como ligandos del receptor vaniloide para el tratamiento del dolor.
WO2004014871A1 (en) 2002-08-08 2004-02-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7245117B1 (en) * 2004-11-01 2007-07-17 Cardiomems, Inc. Communicating with implanted wireless sensor
US7534798B2 (en) 2004-02-11 2009-05-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
PT3109244T (pt) 2004-09-14 2019-06-04 Gilead Pharmasset Llc ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
WO2006089311A1 (en) 2005-02-15 2006-08-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US8158586B2 (en) * 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
EP1877400A1 (de) * 2005-04-15 2008-01-16 Amgen, Inc Vanilloidrezeptorliganden und deren verwendung bei behandlungen
WO2010049947A2 (en) * 2008-10-28 2010-05-06 Accrete Pharmaceutical Private Limited Preparation of gemcitabine and intermediates thereof
CA2764653C (en) * 2009-06-10 2018-01-02 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compounds
TWI526441B (zh) 2010-08-20 2016-03-21 中外製藥股份有限公司 包含四環化合物的組成物
SG10201704588XA (en) 2012-09-25 2017-07-28 Chugai Pharmaceutical Co Ltd Ret inhibitor
CN106458967A (zh) 2014-04-25 2017-02-22 中外制药株式会社 四环化合物的新结晶
CA2946518C (en) 2014-04-25 2022-07-26 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
TWI803187B (zh) 2014-08-08 2023-05-21 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
TWI752901B (zh) 2015-01-16 2022-01-21 日商中外製藥股份有限公司 合併用醫藥
WO2019000224A1 (zh) * 2017-06-27 2019-01-03 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CA3107270A1 (en) 2018-09-04 2020-03-12 Chugai Seiyaku Kabushiki Kaisha Method for producing tetracyclic compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438050A (en) * 1988-02-06 1995-08-01 Godecke Aktiengesellschaft Indolocarbazole derivatives, processes for their preparation and compositions containing them
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
WO1994007895A1 (en) * 1992-09-25 1994-04-14 Schering Corporation Diindolo compounds and pharmaceutical compositions containing them
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
CN1050844C (zh) * 1993-12-07 2000-03-29 伊莱利利公司 蛋白激酶ｃ抑制剂
US5472183A (en) * 1994-03-17 1995-12-05 Nisca Corporation Sheet feeding device with multiple sheet stackers
US5559228A (en) * 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5696949A (en) * 1995-06-15 1997-12-09 Intel Corporation System for PCI slots expansion using asynchronous PCI-to-PCI bridge with clock generator for providing clock signal to the expansion mother board and expansion side of bridge

Also Published As

Publication number Publication date
AU2929297A (en) 1997-11-19
EP0805158B1 (de) 2002-01-16
JP3235840B2 (ja) 2001-12-04
US5936084A (en) 1999-08-10
CZ347098A3 (cs) 1999-06-16
YU48398A (sh) 2000-12-28
PT805158E (pt) 2002-06-28
NZ332658A (en) 2000-05-26
DK0805158T3 (da) 2002-03-18
WO1997041127A1 (en) 1997-11-06
NO985080D0 (no) 1998-10-30
NO310416B1 (no) 2001-07-02
EP0805158A3 (de) 1998-04-01
EA001450B1 (ru) 2001-04-23
JPH11509233A (ja) 1999-08-17
KR20000065137A (ko) 2000-11-06
CA2252701C (en) 2003-10-28
BR9709301A (pt) 1999-08-10
IL126762A0 (en) 1999-08-17
CA2252701A1 (en) 1997-11-06
NO985080L (no) 1998-12-08
AU703395B2 (en) 1999-03-25
TR199802193T2 (xx) 1999-02-22
EP0805158A2 (de) 1997-11-05
DE69709568T2 (de) 2002-09-05
PL329681A1 (en) 1999-04-12
ES2170918T3 (es) 2002-08-16
EA199800966A1 (ru) 1999-04-29
DE69709568D1 (de) 2002-02-21

Similar Documents

Publication Publication Date Title
ATE212026T1 (de) Halo-substituierte protein kinase c inhibitoren
YU70494A (sh) Inhibitori proteinske kinaze c
DE69615674T2 (de) Cyclobutan-derivate als inhibitoren der squalen-synthase und der protein farnesyltransferase
ATE116974T1 (de) 5- piperazinylalkyl-1,5-benzothiazepinone verwendbar als calciumantagonisten.
TW371661B (en) Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
ATE207879T1 (de) Alkynylaminosäure derivate und ihre verwendung als pharmazeutische verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee